Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune approaches to the treatment of breast cancer, around the corner?
Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Criscitiello C, et al. Among authors: fumagalli l. Breast Cancer Res. 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. Breast Cancer Res. 2014. PMID: 25774617 Free PMC article. Review.
Dendritic cell-based vaccines: clinical applications in breast cancer.
Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Gelao L, et al. Among authors: fumagalli l. Immunotherapy. 2014;6(3):349-60. doi: 10.2217/imt.13.169. Immunotherapy. 2014. PMID: 24762078 Review.
Tumour dormancy and clinical implications in breast cancer.
Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G. Gelao L, et al. Among authors: fumagalli l. Ecancermedicalscience. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. Print 2013. Ecancermedicalscience. 2013. PMID: 23717341 Free PMC article.
Targeting the subtypes of breast cancer: rethinking investigational drugs.
Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, Criscitiello C, Goldhirsch A. Curigliano G, et al. Among authors: fumagalli l. Expert Opin Investig Drugs. 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. Expert Opin Investig Drugs. 2012. PMID: 22229343 Review.
Locoregional recurrence in patients with HER2 positive breast cancer.
Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Brollo J, et al. Among authors: fumagalli l. Breast. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. Breast. 2013. PMID: 23642529
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. Criscitiello C, et al. Among authors: fumagalli l. Breast. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. Breast. 2014. PMID: 24314620
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.
Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A. Curigliano G, et al. Among authors: fumagalli l. Breast. 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. Breast. 2015. PMID: 25772326 Clinical Trial.
537 results